Skip to main content
VCYT logo

Veracyte, Inc.

VCYTNASDAQHealthcareDiagnostics & Research

$43.12Today:- (-)1Y +23.89%

As of Oct 16, 2026 close

Market cap
$3.64B
P/E (TTM)
31.82
Forward P/E
15.73
Dividend yield
-
52-week range
$29.46$60.91
Volume (live)
-
Avg. volume (3M)
1.41M

Veracyte (VCYT) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Veracyte generated $136.31M of operating cash flow and spent $9.68M on capital expenditures. That left free cash flow of $126.63M, up 98.5% from $63.81M a year earlier, or 24.5% of revenue. It repurchased $18.30M of its own shares.

Veracyte Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Veracyte, Inc. (VCYT) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
Operating Activities
Net Income66.3524.14-74.40-36.56-75.56-34.91-12.60-23.00-31.00
Depreciation & Amortization21.4223.4627.1925.9319.597.944.123.923.84
Deferred Income Tax-0.58-0.23-3.840.13-6.260.00-0.020.000.01
Stock Based Compensation43.6036.2533.1426.7322.5213.009.815.966.62
Change in Working Capital-2.30-20.97-3.70-16.384.22-0.48-4.85-0.65-5.44
Change in Accounts Receivable-0.71-6.413.89-4.50-8.570.96-6.16-0.45-3.96
Change in Inventory-2.86-5.87-1.69-3.01-1.461.06-3.401.92-1.85
Change in Accounts Payable-1.04-4.31-0.130.155.160.71-0.14-1.571.73
Change in Other Working Capital-12.307.12-5.75-9.032.66-3.214.86-0.55-1.36
Other Operating Activities-12.307.1265.837.682.664.740.310.252.06
Net Cash from Operating Activities136.3175.1044.227.54-31.62-9.71-3.23-13.52-23.92
Investing Activities
Capital Expenditures-9.68-11.29-9.96-8.55-5.38-2.84-2.76-1.87-1.76
Acquisitions-2.855.010.000.00-736.830.00-40.000.000.44
Purchases of Investments-150.00-50.00-19.70-33.52162.42-1.000.000.000.00
Sales/Maturities of Investments153.310.0044.7712.683.000.000.000.000.00
Other Investing Activities-2.850.000.000.00-162.420.000.020.000.56
Net Cash from Investing Activities-9.21-56.2815.11-29.39-739.21-3.84-42.73-1.87-1.20
Financing Activities
Debt Repayment0.000.000.00-1.280.00-0.10-25.21-0.29-2.32
Common Stock Issued14.0819.990.000.00593.82193.83137.8555.040.20
Common Stock Repurchased-18.30-10.590.000.000.000.000.000.000.00
Other Financing Activities-18.30-15.092.844.78-9.039.8614.654.751.90
Net Cash from Financing Activities-4.224.902.843.49596.32203.60127.2959.50-0.22
Summary
Effect of Forex Changes on Cash0.72-0.420.16-0.59-1.510.000.000.000.00
Net Change in Cash122.8823.7362.33-18.95-174.51190.0581.3244.10-25.33
Cash at Beginning of Period240.63217.33155.00173.95349.97159.9278.6034.4959.22
Cash at End of Period364.23240.63217.33155.00173.95349.97159.9278.6033.89
Free Cash Flow126.6363.8134.26-1.01-37.00-12.55-5.99-15.40-25.67
Supplemental Disclosures
Interest Paid---0.010.010.01---
Income Taxes Paid-2.241.700.570.110.11---

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Veracyte Cash Flow

What is Veracyte's free cash flow?

Veracyte generated free cash flow of $126.63M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of $136.31M minus $9.68M of capital expenditures. That was up 98.5% from $63.81M a year earlier. Free cash flow equaled 24.5% of revenue.

How much does Veracyte spend on capital expenditures?

Veracyte spent $9.68M on capital expenditures in fiscal 2025, compared with $11.29M a year earlier. That equals 7.1% of operating cash flow.

Does Veracyte pay dividends or buy back shares?

Yes. In fiscal 2025 Veracyte returned $18.30M in share buybacks to shareholders, according to its cash flow statement.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition